The age of participants at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

The height of participants at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria. Here, number analyzed represents the number of participants evaluable for the outcome measure.

The body weight of participants at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria. Here, number analyzed represents the number of participants evaluable for the outcome measure.

The body mass index (BMI) of participants at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria. Here, number analyzed represents the number of participants evaluable for the outcome measure.

The C-reactive protein levels of participants at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria. Here, number analyzed represents the number of participants evaluable for the outcome measure.

The estimated Glomerular Filtration Rate (eGFR) is an index of kidney function. eGFR was calculated using factors such as serum creatinine level, age, sex, and in millimeter per minute per 1.73 square meter (ml/min/1.73 m^2), and tabulated in three categories (<60, ≥60, unknown). An eGFR <60 indicates some degree of kidney impairment. And eGFR > 60 is generally considered to be within the normal range.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

The smoking history status of participants at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

ECOG-PS assessed participant's performance status on a 5 point scale: 0= fully active/able to carry on all pre-disease activities without restriction; 1= restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2= ambulatory (>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3= capable of only limited self-care, confined to bed/chair >50% of waking hours; 4= completely disabled, cannot carry on any self-care, totally confined to bed/chair.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria. Here, number analyzed represents the number of participants evaluable for the outcome measure.

The Number of participants with Metastatic Organs of participants at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

TX: Primary tumor cannot be assessed, T0: No evidence of primary tumor, T1: Tumor ≤7 cm in greatest dimension, limited to the kidney, T1a: Tumor≤4cm in greatest dimension, limited to the kidney, T1b: Tumor>4 cm but ≤7 cm in greatest dimension, limited to the kidney, T2: Tumor >7 cm in greatest dimension, limited to the kidney, T2a: Tumor >7 cm but ≤10 cm in greatest dimension, limited to the kidney, T2b: Tumor >10 cm, limited to the kidney, T3: Tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia,T3a: Tumor extends into the renal vein or its segmental branches, or invades the pelvicalyceal system, or invades perirenal and, T3b: Tumor extends into the vena cava below the diaphragm, T3c: Tumor extends into the vena cava above the diaphragm or invades the wall of the vena cava, T4: Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)

The Efficacy Analysis Set is a subset of the FAS comprising patients whose index date is prior to April 30, 2022, to ensure a 6-month follow-up period.

Lymph node metastasis (N factor) of participants at baseline was reported. NX: Regional lymph nodes cannot be assessed, N0: No regional lymph node metastasis, N1: Metastasis in regional lymph node(s).

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Distant metastasis (M factor) of participants at baseline was reported. M0: No distant metastasis, M1: Distant metastasis.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Tumor histological type of participants at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Number of Participants with Presence or Absence of Sarcomatoid Component at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria. . Here "Number of Participants Analyzed" signifies those participants who were evaluated at the specified time point.

The four-tiered Fuhrman grading evaluates nuclear size, nuclear shape and presence of nucleolar prominence. Grade 1: small (=10 micrometer [mcm]) nuclear diameter, round/uniform nuclear shape and absent/inconspicuous nucleoli; Grade 2: large (=15 mcm) nuclear diameter, irregular outline nuclear shape and visible at *400 magnification nucleoli; Grade 3: larger (=20 mcm) nuclear diameter, obvious irregular outline nuclear shape and visible and prominent at *100 magnification nucleoli; Grade 4: grade 3 plus bizarre multilobed nuclei +/- spindle cells. Participants whose Fuhrman Grade were not known were reported against "Unknown'.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Proteinuria is the presence of an excess of serum proteins in the urine, which may be an early sign of kidney disease. Here, negative (-)= <15 milligrams per deciliter (mg/dL) (Normal), positive (±) =15-29 mg/dL (increased risk for kidney disease), (1+) = 30 mg/dL(Early stages of kidney disease), (2+)= 100 mg/dL (Underlying kidney disease), (3+)= 300 mg/dL (kidney dysfunction).

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Performance of nephrectomy at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Number of Participants with Presence or absence of clinically important comorbidities at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Number of participants with Presence or absence of clinically important concomitant drugs at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Number of Participants with Initiation of Systemic Therapy within One Year of Diagnosis was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Karnofsky performance score was used to quantify participant's general well-being and activities of daily life and participants were classified based on their functional impairment. Karnofsky performance score ranges between 0 (death) to 100 (no evidence of disease). Higher score means higher ability to perform daily tasks.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Number of participants with Hemoglobin value below the lower normal limit at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Number of participants with Corrected calcium value above the upper normal limit at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Number of Participants with Neutrophil count above the upper normal limit at baseline was reported.

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

IMDC criteria had 6 risk factors: Karnofsky Performance Status less than (<) 80% (ability to perform ordinary tasks, 0 [dead] -100 [normal]); time from diagnosis to start of systemic therapy <1 year; corrected serum calcium; neutrophils and platelets more than (>) upper limit of normal (ULN); hemoglobin <lower limit of normal (LLN). Present risk factors were added, and then participants were stratified as: Low risk (0 factor), Medium risk (1-2 factors), High risk (more than or equal to [>=]3 factors).

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

Number of risk factors in participants at baseline was reported

The Full Analysis Set comprised of participants who met the inclusion criteria and did not meet the exclusion criteria.

rwPFS is defined as: The time from start of avelumab plus axitinib therapy to date of first disease progression (as clinically assessed by local investigator based on radiology, laboratory evidence, pathology, or other assessments) or death due to any cause, whichever occurred first.

The efficacy analysis set is a subset of the FAS that includes patients whose index date is prior to 30 April 2022 to ensure a 6-months follow-up period.

TTD is defined as the time from the start of treatment with avelumab plus axitinib to the end of treatment due to any cause except the effectiveness of the treatment.

The efficacy analysis set is a subset of the FAS that includes patients whose index date is prior to 30 April 2022 to ensure a 6-months follow-up period.

OS is defined as the time from the start of treatment with avelumab plus axitinib to the date of death due to any cause. If there are no clinical records of death, the date when the patient was last documented to be alive will be confirmed based on medical records. The data will be censored at the date of last contact.

The efficacy analysis set is a subset of the FAS that includes patients whose index date is prior to 30 April 2022 to ensure a 6-months follow-up period.

The ORR is defined as the proportion of participants with a documented BOR (complete response (CR) or partial response (PR)) by the investigator during treatment with avelumab plus axitinib as firstline therapy. The BOR is defined as the best tumor response recorded during the observation period. The definitions of tumor responses are as follows: Complete or PR as the best adjudication result (CR > PR > stable disease [SD] > progressive disease [PD], not Evaluable [NE]) complies with the RECIST tumor assessment guidelines as closely as possible in clinical practice.

The efficacy analysis set is a subset of the FAS that includes patients whose index date is prior to 30 April 2022 to ensure a 6-months follow-up period.

BOR is the best tumor response recorded during observation period.Tumor response are defined as follows:Complete or PR as the best adjudication result (CR > PR > stable disease [SD] > progressive disease [PD],not Evaluable[NE]) in a method complied with RECIST version. 1.1tumor assessment as closely as possible in clinical practice by investigator's judgment.CR:Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR:Atleast 30% decrease in sum of diameters of target lesions,taking as reference the baseline sum diameters.SD:Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD,taking as reference the smallest sum diameters. PD:atleast a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm.

The efficacy analysis set is a subset of the FAS that includes patients whose index date is prior to 30 April 2022 to ensure a 6-months follow-up period. Here "Number of Participants Analyzed" signifies those participants who were evaluated at the specified time point.